We develop novel therapies to address high unmet medical need where metabolic dysregulation is a core disease driver.
Ultimately, liver fibrosis may progress to cirrhosis (severe scarring) and liver cancer. People with NASH and mild liver scarring (fibrosis) may or may not experience symptoms, but severe scarring (cirrhosis) increases risk of liver failure and death.
Effective treatment of NASH requires intervening across stages of disease progression, addressing both the early-stage metabolic drivers and later-stage inflammation and fibrosis
We believe restoring whole-body metabolic balance is essential to treating NASH. Our lead program, EFX, has yielded promising data showing potential to address the diverse drivers of NASH pathology.